Invion Reports 79% Disease Control in Phase 1 Skin Cancer Trial
Invion closed Phase 1 recruitment in non-melanoma skin cancer, reporting 79% disease control across 14 patients — an early signal now awaiting full data readout.
Stories
Tom Whitfield
Stories
Tom Whitfield
AAFP Publishes Melanoma Diagnosis and Treatment Guidance
The AAFP has published a clinical review, "Melanoma: Diagnosis and Treatment," guiding family physicians on lesion assessment, bi…
Nebraska Clinics Offer New Therapy for Ocular Melanoma Liver Spread
Nebraska providers now offer a new treatment for rare uveal melanoma that spreads from the eye to the liver, giving regional pati…
Bemotrizinol's Approval Prompts Five Questions Patients Will Ask
FDA approval of bemotrizinol sends dermatology clinics a wave of patient questions. AJMC lays out five clinicians should be ready…
Week 4 on Abrocitinib Predicts Week 12 Remission in Atopic Dermatitis
A JAAD study published October 17, 2026 finds week 4 abrocitinib response predicts week 12 remission in moderate-to-severe atopic…
JAAD Examines Lymphoma Risk Signals in Hidradenitis Suppurativa
JAAD published online October 17, 2026 an analysis by Islam, Islam and Wu on interpreting lymphoma risk in hidradenitis suppurati…
Atopic Dermatitis Is Systemic, and 'Doing Nothing' Has a Cost
Dermatology Times argues untreated atopic dermatitis isn't neutral: reframed as a systemic inflammatory disease, inaction carries…
Psoriasis Care Shifts Focus Beyond Skin Clearance Alone
A Physician's Weekly feature argues psoriasis care should extend beyond plaque clearance to joints, comorbidities and quality of…
Galderma Buys ZO Skin Health for $1.5 Billion
Galderma will buy ZO Skin Health from Blackstone and the Obagi family for $1.5 billion, adding the physician-dispelled skincare b…
Topical Febuxostat Quiets Psoriasis in Mouse Model, Bioengineer Reports
A gout pill reformulated as a skin rub cleared psoriasis-linked inflammation in mice, per Bioengineer.org. The xanthine oxidase i…